III. Contraindications
- Penile deformity (e.g Peyronie's Disease)
- Sexual intercourse with pregnant women
- Risk of Preterm Labor
- Priapism risk
IV. Preparation
- Transurethral preparation
- Inserted 3 cm into Urethra with plastic applicator
- Semi-solid pellet
- Diameter: 1.4 mm
- Length: 3-6 mm
V. Efficacy
- Successful intercourse in 65% of 1511 tested
- Placebo success rate: 19%
- Less effective than injectable alprostadil
VI. Adverse effects
- Hypotension (3%)
- Dizziness (2%)
- Mild Erectile discomfort (32%)
- Minor Urethral burning or bleeding
- Priapism is rare
VII. Dosing
- Dose 125-1000 ug ($114-$137 for 6 units)
VIII. Reference
Images: Related links to external sites (from Bing)
Related Studies
Concepts | Pharmacologic Substance (T121) , Eicosanoid (T111) |
MSH | D000527 |
English | Prostin VR Pediatric, prostin vr, prostin vr pediatric, Astra Brand of Alprostadil, Janssen Brand of Alprostadil, Prostin VR, Minprog, Prostine VR, AstraZeneca Brand of Alprostadil, Paladin Brand of Alprostadil, Pharmacia Brand 1 of Alprostadil, Vivus Brand of Alprostadil, Abbott Brand of Alprostadil |
French | Prostine VR |